SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 55 of 85
Word Count: 1420
Character Count: 8722

Document Content:

above. Director Compensation Name Fees earned or paid in cash ($) Stock awards ($) Option awards ($) Non-equity incentive plan compensation ($) Nonqualified deferred compensation earnings ($) All other compensation ($) Total ($) Mark Ravich - - $ 18,012 (2) - - - $ 18,012 William Abraham - - $ 18,012 (2) - - - $ 18,012 Rishi Puri - - $ 18,012 (2) - - - $ 18,012 of December 31, 2025, each non-employee director held 18,012 option awards and no restricted stock awards. (2) Amounts reflect the full grant-date fair value of stock option awards granted during the applicable fiscal year computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the non-employee director. We provide information regarding the assumptions used to calculate the value of all awards made to our directors in Note 9 of the Consolidated Financial Statements. Director Compensation

Other
than as set forth in the table above relating to their capacity as officers, our board members did not pay any compensation, reimburse
any expense of, make any equity awards or non-equity awards to, or pay any other compensation to, any of the other non-employee members
of the Board in the fiscal year ended December 31, 2025. In connection with the closing of this offering, we plan to establish a non-employee
director compensation program, the terms of which have yet to be determined. On January 2, 2026, each non-employee director was granted
30,000 restricted stock awards.

Summary
of Material Terms of the 2024 Plan

The
following is a summary of the material features of the BioVentrix, Inc. 2024 Equity Incentive Plan (the “2024 Plan”).

Eligibility

The
Administrator may grant awards to any director, employee or consultant of the Company or its affiliates. Only employees are eligible
to receive incentive stock options.

Administration

The
2024 Plan is administered by the Board of Directors (the “Board”) or one more committees or subcommittees of the Board, (collectively,
the “Administrator”). The Administrator has the authority to construe and interpret the 2024 Plan and the awards granted
under it, and to establish, amend, and revoke rules and regulations for its administration. The Administrator may correct any defect,
omission, or inconsistency in the 2024 Plan or in any award in a manner and to the extent it deems necessary or expedient to make the
2024 Plan fully effective.

Share
Reserve

The
maximum aggregate number of shares of our common stock (the “Shares”) that may be issued under the 2024 Plan is 1,500,000.

Shares may be issued upon the exercise of incentive stock options.

The
share reserve described herein may be subject to certain adjustments in the event of certain changes in our capitalization (see Equitable
Adjustments below).

Types
of Awards

The
2024 Plan provides for the grant of stock options (both incentive stock options and nonqualified stock options) and restricted stock
(collectively, “awards”).

Stock
Options. The 2024 Plan permits the granting of both options intended to qualify as incentive stock options under Section 422 of the Internal
Revenue Code of 1986, as amended (the “Code”) and options that do not so qualify. Options granted under the 2024 Plan will
be nonqualified options if they fail to qualify as incentive stock options or exceed the annual limit on incentive stock options. Incentive
stock options may only be granted to our employees. Nonqualified options may be granted to any persons eligible to receive awards under
the 2024 Plan.

The
exercise price of each option will be determined by the Administrator, but such exercise price may not be less than 100% of the fair
market value of one Share on the date of grant or, in the case of an incentive stock option granted to a 10% or greater stockholder,
110% of such Share’s fair market value. The term of each option will be set by the Administrator and may not exceed ten (10) years
from the date of grant (or five (5) years for an incentive stock option granted to a 10% or greater stockholder). The Administrator will
determine at what time or times each option may be exercised, including the ability to accelerate the vesting of such options.

Restricted
Stock. A restricted stock award is an award of Shares that vests in accordance with the terms and conditions established by the Administrator.
The Administrator will determine the persons to whom grants of restricted stock awards are made, the number of restricted shares to be
awarded, the price (if any) to be paid for the restricted shares, the time or times within which awards of restricted stock may be subject
to forfeiture, the vesting schedule and rights to acceleration thereof, and all other terms and conditions of restricted stock awards.
Unless otherwise provided in the applicable award agreement, a participant generally will have the rights and privileges of a stockholder
as to such restricted shares, including, without limitation, the right to vote such restricted shares and the right to receive cash dividends,
if applicable.

Equitable
Adjustments

any change is made in the Shares subject to the 2024 Plan, or subject to any stock award, without the receipt of consideration (through
merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock
split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving
the receipt of consideration by us), the 2024 Plan will be appropriately adjusted in the class(es) and maximum number of securities subject
to the 2024 Plan and the outstanding awards will be appropriately adjusted in the class(es) and number of securities and price per Share
subject to such outstanding awards.

Change
in Control

the event of (x) a sale, lease or other disposition of all or substantially all of our assets, (y) a merger or consolidation in which
we are not the surviving corporation or (z) a reverse merger in which we are the surviving corporation but the Shares outstanding immediately
preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise,
all options outstanding under the 2024 Plan will be treated in the manner described in the definitive transaction agreement approved
by the Board, which agreement need not treat all options outstanding in an identical manner. Such treatment may include, without limitation,
one or more of the following with respect to each outstanding option outstanding under the 2024 Plan: (i) continuation of the option
by the us (if we are the surviving entity in the transaction), (ii) assumption of the option by the surviving corporation or its parent
in a manner that complies with applicable law and tax provisions, (iii) substitution by the surviving corporation or its parent of a
new option or stock purchase right for the option in a manner than complies with applicable law and tax provisions, (iv) cancellation
of the option and a payment of the spread (unless such option is underwater, in which case it may be cancelled for no payment), (v) cancellation
of the option without the payment of any consideration; provided that the optionholder will be notified of such treatment and given an
opportunity to exercise the option to the extent vested, (vi) suspension of the optionholder’s right to exercise the option during
a limited period of time preceding the closing if such suspension is administratively necessary to permit the closing of the transaction,
and/or (vii) termination of any right of an optionholder has to exercise the option prior to vesting in the shares subject to the option,
such that at or following the closing of the transaction, the option may only be exercised to the extent it is vested, in each case,
as determined by the Board.

Term

The
2024 Plan became effective upon approval by the Board on August 7, 2024, but was terminated in connection with our adoption of the 2026
Plan, as discussed below. Awards made under the 2024 Plan will remain subject to the terms and conditions of such plan until they vest,
expire, or are forfeited. Following the termination of the 2024 Plan, no further awards may be made under the 2024 Plan.

Summary
of Material Terms of the 2026 Plan

The
following is a summary of the material features of the BioVentrix, Inc. 2026 Equity Incentive Plan (the “2026 Plan”), which
was adopted by the Board and our stockholders on [________].

Eligibility

The
Administrator may grant awards to any director, employee or consultant of the Company or its subsidiaries. Only employees are eligible
to receive incentive stock options.

Administration